Den europeiske union - estisk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - antineoplastilised ained - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Den europeiske union - estisk - EMA (European Medicines Agency)

bayer ag - telmisartan, hydrochlorothiazide - hüpertensioon - reniini-angiotensiini süsteemi toimivad ained - essentsiaalse hüpertensiooni ravi. pritorplus fikseeritud annuse kombinatsioon (40 mg telmisartan / 12. 5 mg hydrochlorothiazide, 80mg telmisartan / 12. 5 mg hydrochlorothiazide) on näidustatud patsientidele, kelle vererõhk ei ole adekvaatselt kontrollitav kohta telmisartan üksi. pritorplus fikseeritud annuse kombinatsioon (80 mg telmisartan / 25 mg hydrochlorothiazide) on näidustatud patsientidele, kelle vererõhk ei ole adekvaatselt kontrollitav kohta pritorplus (80 mg telmisartan / 12. 5 mg hydrochlorothiazide) või patsientidel, kes on eelnevalt stabiliseeritud kohta telmisartan ja hydrochlorothiazide antud eraldi.

Den europeiske union - estisk - EMA (European Medicines Agency)

krka, d.d., novo mesto - telmisartan, hydrochlorothiazide - hüpertensioon - telmisartan ja diureetikumid - tolucombi fikseeritud annuse kombinatsioon (80 mg telmisartaani / 25 mg hüdroklorotiasiidi) on näidustatud täiskasvanutel, kellel vererõhku ei kontrollita piisavalt tolucombi 80 mg / 12. 5 mg (80 mg telmisartaani / 12. 5 mg hüdroklorotiasiidi) või täiskasvanutel, kes on eelnevalt eraldi telmisartaani ja hüdroklorotiasiidi suhtes stabiliseerunud.

Estland - estisk - Ravimiamet

sandoz pharmaceuticals d.d. - telmisartaan+hüdroklorotiasiid - kaetud tablett - 40mg+12,5mg 56tk; 40mg+12,5mg 30tk; 40mg+12,5mg 100tk

Estland - estisk - Ravimiamet

teva b.v. - telmisartaan+hüdroklorotiasiid - tablett - 80mg+12,5mg 14tk; 80mg+12,5mg 90tk; 80mg+12,5mg 250tk; 80mg+12,5mg 30tk; 80mg+12,5mg 56tk; 80mg+12,5mg 98tk; 80mg+12,5mg 28tk

Estland - estisk - Ravimiamet

zentiva k.s. - telmisartaan+hüdroklorotiasiid - tablett - 80mg+25mg 28tk; 80mg+25mg 84tk; 80mg+25mg 98tk; 80mg+25mg 90tk; 80mg+25mg 14tk; 80mg+25mg 56tk

Estland - estisk - Ravimiamet

tad pharma gmbh - telmisartaan+hüdroklorotiasiid - tablett - 40mg+12,5mg 56tk; 40mg+12,5mg 14tk; 40mg+12,5mg 30tk; 40mg+12,5mg 90tk; 40mg+12,5mg 10tk; 40mg+12,5mg 84tk; 40mg+12,5mg 28tk; 40mg+12,5mg 98tk; 40mg+12,5mg 60tk

Estland - estisk - Ravimiamet

teva b.v. - telmisartaan+hüdroklorotiasiid - tablett - 80mg+25mg 250tk; 80mg+25mg 14tk; 80mg+25mg 28tk; 80mg+25mg 98tk; 80mg+25mg 90tk; 80mg+25mg 30tk

Estland - estisk - Ravimiamet

roche eesti osaühing - alfa-2a-interferoon - süstelahus - 9000000rÜ 0.5ml 12tk; 9000000rÜ 0.5ml 1tk; 9000000rÜ 0.5ml 6tk; 9000000rÜ 0.5ml 5tk

Estland - estisk - Ravimiamet

accord healthcare b.v. - telmisartaan+hüdroklorotiasiid - tablett - 80mg+25mg 90tk; 80mg+25mg 84tk; 80mg+25mg 28tk; 80mg+25mg 98tk; 80mg+25mg 100tk; 80mg+25mg 60tk; 80mg+25mg 14tk